The Abuse Potential of Remoxy®, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone

Pain Medicine

Volumn 12, Issue 4, 2011, Pages 618-631

  Setnik, Beatrice ^a   Roland, Carl L ^a   Cleveland, Jody M ^a   Webster, Lynn ^b  

^a King Pharmaceuticals   (United States)

^b Lifetree Clinical Research and Pain Clinic   (United States)

Author keywords

Abuse; Liability; Oxycodone; Potential; Remoxy

Indexed keywords

OXYCODONE; PARACETAMOL; PLACEBO;

ADULT; ADVERSE DRUG REACTION; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOSAGE FORMS; DOUBLE-BLIND METHOD; FASTING; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; OXYCODONE; PLACEBOS; QUESTIONNAIRES; YOUNG ADULT;

EID: 79954848941     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01093.x     Document Type: Article

References (21)

1. American Pain Foundation. Pain facts and figures. 2010. Available at: (accessed August 2, 2010).
2. Chou R, Fanciullo GJ, Fine PG, etal. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30.
3. Parsells Kelly J, Cook SF, Kaufman DW, etal. Prevalence and characteristics of opioid use in the US adult population. Pain 2008;138(3):507-13.
4. Substance Abuse and Mental Health Services Administration. Results from the 2008 national survey on drug use and health: national findings. NSDUH Series H-36 Publication No SMA 09-4434. 2009 Available at: (accessed October 20, 2010).
5. Substance Abuse and Mental Health Services Administration. Treatment episode data set (TEDS) highlights-2007. National admissions to substance abuse treatment services. DASIS Series: S-45. DHHS Publication No. (SMA) 09-4360. 2009. Available at: (accessed August 3, 2010).
6. Johnston LD, O'Malley PM, Bachman JF, Schulenberg JE. Monitoring the future national results on adolescent drug use: Overview of key findings. NIH publication No. 09-7401. 2008 Available at: (accessed October 19, 2009).
7. US General Accounting Office. Prescription drugs, OxyContin abuse and diversion, and efforts to address the problem. 2003 Available at: (accessed July 20, 2010).
8. Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 1996;42(6):747-56.
9. Martins SS, Storr CL, Zhu H, Chilcoat HD. Correlates of extramedical use of OxyContin versus other analgesic opioids among the US general population. Drug Alcohol Depend 2009;99(1-3):58-67.
10. Webster LR. PTI-821: Sustained-release oxycodone using gel-cap technology. Expert Opin Investig Drugs 2007;16(3):359-66.
11. US Food and Drug Administration. FDA approves new formulation of OxyContin. 2010. Available at: (accessed February 9, 2011).
12. Substance Abuse and Mental Health Services Administration. Results from the 2009 national survey on drug use and health: volume II. Technical Appendices and Selected Prevalence Tables (Office of Applied Studies, NSDUH Series H-38B, HHS Publication No. SMA 10-4856 Appendices). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2010.
13. U.S. Food and Drug Administration. OxyContin-questions and answers. 2010. Available at: (accessed February 7, 2011).
14. Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 2003;70(suppl 3):S41-54.
15. Food and Drug Administration. Draft Guidance for Industry: Assessment of Abuse Potential of Drugs. Silver Springs, MD: U.S. Department of Health and Human Services; 2010.
16. Benziger DP, Kaiko RF, Miotto JB, etal. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J Pharm Sci 1996;85(4):407-10.
17. Cole JO, Orzack MH, Beake B, Bird M, Bar-Tal Y. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 1982;43(12 Pt 2):69-75.
18. Shram MJ, Sathyan G, Khanna S, etal. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol 2010;30(1):25-33.
19. Cole JO, Levin A, Beake B, Kaiser PE, Scheinbaum ML. Sibutramine: A new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol 1998;18(3):231-6.
20. National Drug Intelligence Center. OxyContin diversion and abuse. 2001 Available at: (accessed August 2, 2010).
21. Benjamini Y, Hochberg M. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57(1):289-300.